KTB-KORUS Fund

KTB-KORUS Fund is a venture capital firm that invests in early-stage companies, primarily within the biotech and technology sectors, operating with a US entity as part of the broader KTB Network. As an extension of KTB Network, one of Korea's first VC firms, it has seen over 250 portfolio companies go public, accounting for more than 10% of all Korean IPOs. The fund focuses on opportunities in biotech and biomedical research, with a notable investment in ORIG3N, a stem cell and DNA testing company. KTB-KORUS Fund has participated in funding rounds alongside firms such as Hatteras Venture Partners, Syno Capital, and LabCorp, including ORIG3N's $12.5 million round. KTB Network, the parent organization, was established in 1981. Its business model centers on makes money through investments in portfolio companies, with exits via IPOs, over 250 companies have gone public, representing over 10% of Korean IPOs.